History of Research and Development

History of Research and Development

  • Nittobo Group
  • Medical Division
  • Specialty Chemicals Division
  • 1963
  • Succeeded in the industrial synthesis of polyamine sulfone ahead of the rest of the world
  • 1966
  • Commenced sales of DANFIX® (direct dye fixing agent) as an industry first
  • 1974
  • Commenced sales of PAS as pickling inhibitor and zinc plating auxiliary agent
  • 1977
  • Licensed patents for amino acid protective agents to domestic chemical product manufacturers
  • 1979
  • Commenced sales of DANFIX® (reactive dye fixing agent)
  •  
  • Commenced sales of PAS as a fixing agent for paper making sizing agents
  • 1981
  • Commenced supply of in vitro diagnostic pharmaceutical raw materials (synthetic substrate) to domestic diagnostic pharmaceutical manufacturers
  • 1982
  • Commenced manufacturing and sales of blood clotting factor diagnostic reagents
  •  
  • Commenced OEM supply of in vitro diagnostic reagents to domestic diagnostic reagent manufacturers
  • 1984
  • Invented and commenced sales of PAA® (Polyallylamine) polymerization process
  • 1986
  • Developed applications and commenced sales of PAA® series as ink fixing agent for inkjet printer paper
  • 1987
  • Established PAA® hydrochloride desalination technology
  •  
  • Commenced manufacture and sales of in vitro diagnostic reagents
  •  
  • Established Midland BioProducts Corporation (MBC)
    Product antiserum, etc. at Nittobo America Inc. (California, Iowa)

    With expecting the market expansion for immunological diagnostic reagents, we started working in cooperation with International Immunology Corporation and Midland BioProducts Corporation (currently, Nittobo America Inc.). They manufacture the antiserums that are the raw materials of immunological diagnostic reagents. The company made stable supply of high quality end products by consistently manufacturing from raw materials to finished products within the Nittobo Group.

  • 1988
  • Commenced sales of immune system serology diagnostic reagent
  • 1989
  • Synthesis and application development of PAS (ampholytic type)
  • 1991
  • Developed applications and commenced sales of low-molecular weight PAA® as a direct dye fixing agent
  • 1994
  • Commenced sales of POLYFLOC® (flocculatin agent)
  • 1996
  • Established production method for N-allyl urethane PAA®
  • 1997
  • Established production method and commenced sales of low-molecular weight PAA®
  •  
  • Filed international patent application for manufacture of poly N, N-dialkylallylamine
  • 1998
  • Established production method for high-purity PAA®
  •  
  • Commenced full-scale OEM supply to overseas companies
  • 1999
  • Commenced production and sales of high-molecular-weight PAA®
  • 2002
  • Commenced sales of amphoteric polymers for cleaning agent applications
  • 2003
  • Commenced sales of PAS for ink additive applications
  •  
  • Established production method for PAS low-chloro-type
  •  
  • Commenced joint research into insect technology with the National Institute of Agrobiological Sciences
  • 2006
  • Commenced sales of PAA® alcohol solvent type
  •  
  • Succeeded in production of antibody-producing genetically-modified silkworms
  • 2008
  • Commenced sales of DANFLAT® (copper and zinc plating auxiliary agent)
  •  
  • Marker for bone metabolism "TRACP-5b" production and sales are approved; sales commenced
  • 2010
  • Commenced sales of DANCATCH® (deodorizing agent)
  •  
  • Commenced sales of SSG® HB series (Single-liquid cold-setting type material)
  •  
  • Commenced sales of MOKUTO® (special liquid glass paint for natural wood)
  •  
  • Commenced sales of SSG® ME Series (Single-liquid cold-setting type; hard-coating agent for metals)
  • 2015
  • Commenced sales of DANCHANGE® (temperature-responsive polymer)
  •  
  • Commenced sales of "rapid BACpro®" preparation kit for rapid bacterial identification of bacteria
  •  
  • Awarded the Minister of Agriculture, Forestry and Fisheries Award for the development of in vitro diagnostic reagent using genetically modified silkworms
    Awarded the Minister of Agriculture, Forestry and Fisheries Award for the development of in vitro diagnostic reagent using genetically modified silkworms

    Up to now, human osteoporosis diagnostic reagents have used raw material proteins derived from human bone, and inflammatory response measuring reagents for animals have used protein derived from canine blood.
    However, due to the difficulties in ensuring stable supply of the raw materials, and from an ethics and animal welfare standpoint, there have been calls for substitutes. At Nittobo Medical, we have researched methods for producing the required raw material proteins artificially. We took on the challenge of solving the problem with genetic engineering technology.
    First, we conducted repeated experiments using a variety of specimens, such as cultured mammalian cells, cultured insect cells, yeast and E. coli; however, we could not satisfy both the cost and quality requirements. Therefore, we turned our attention to a method using genetically-modified silkworms. We began a joint research project with the National Institute of Agrobiological Sciences (now the National Agriculture and Food Research Organization). Through the cross-breeding and subculture, we established techniques for extracting and purifying the raw material proteins of interest. By using these raw material proteins, which can now be stably supplied at low cost, we were able to commercialize the osteoporosis diagnostic reagent "TRACP-5b" and the canine CRP measurement reagent "TIA CRP-K9 ". These initiatives were highly rated, and we were awarded the Minister of Agriculture, Forestry and Fisheries Prize in 2015.

  • 2018
  • Established Nittobo NI-Tech Laboratory
    Nittobo NI-Tech Laboratory was established in Innovation Center of Nano Medicine.

    Nittobo NI-Tech Laboratory was established to accelerate the creation of new materials, including medical diagnostic technologies that can be developed globally in a research environment suitable for open innovation. We promote our initiative to build an international collaborative research system as well.

  •  
  • Commenced sales of N-Assay LA IgG4 Nittobo